{
    "info": {
        "nct_id": "NCT03213704",
        "official_title": "NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions",
        "inclusion_criteria": "* APEC1621SC: Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621A based on the presence of an actionable mutation as defined in APEC1621SC\n* Patients must be >= than 12 months and =< 21 years of age at the time of study enrollment\n* Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT; Note: The following do not qualify as measurable disease:\n\n  * Malignant fluid collections (e.g., ascites, pleural effusions)\n  * Bone marrow infiltration except that detected by MIBG scan for neuroblastoma\n  * Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma\n  * Elevated tumor markers in plasma or cerebrospinal fluid (CSF)\n  * Previously radiated lesions that have not demonstrated clear progression post radiation\n  * Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1\n* Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score\n* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required time frame, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately\n\n  * Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\n\n    * >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)\n  * Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil [ANC] counts): >= 7 days after the last dose of agent; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment\n  * Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1\n  * Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\n  * Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator\n  * Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)\n  * Stem cell Infusions (with or without total body irradiation [TBI]):\n\n    * Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)\n    * Autologous stem cell infusion including boost infusion: >= 42 days\n  * Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells, etc.)\n  * Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial brain metastases (BM) radiation; Note: radiation may not be delivered to \"measurable disease\" tumor site(s) being used to follow response to subprotocol treatment\n  * Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy\n  * Patients must not have received prior exposure to other NTRK inhibitors including but not limited to LOXO-101 (larotrectinib), entrectinib (RXDX-101), DS6051, PLX7486\n* For patients with solid tumors without known bone marrow involvement:\n\n  * Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (within 7 days prior to enrollment)\n  * Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (within 7 days prior to enrollment)\n* Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity\n* Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 (within 7 days prior to enrollment) or\n* A serum creatinine based on age/gender as follows (within 7 days prior to enrollment):\n\n  * Age: 1 to < 2 years; maximum serum creatinine (mg/dL); male: 0.6 female: 0.6\n  * Age: 2 to < 6 years; maximum serum creatinine (mg/dL); male: 0.8 female: 0.8\n  * Age: 6 to < 10 years; maximum serum creatinine (mg/dL); male: 1 female: 1\n  * Age: 10 to < 13 years; maximum serum creatinine (mg/dL); male: 1.2 female: 1.2\n  * Age: 13 to < 16 years; maximum serum creatinine (mg/dL); male: 1.5 female: 1.4\n  * Age: >= 16 years; maximum serum creatinine (mg/dL); male: 1.7 female: 1.4\n* Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)\n* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment); (for the purpose of this study, the ULN for SGPT is 45 U/L)\n* Serum albumin >= 2 g/dL (within 7 days prior to enrollment)\n* Patients with seizure disorder may be enrolled if on anti-convulsants and well controlled\n* Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflect (DTR); any grade of DTR is eligible\n* All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines\nHealthy volunteers allowed\nMust have minimum age of 12 Months\nMust have maximum age of 21 Years",
        "exclusion_criteria": "* Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment\n* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid\n* Patients who are currently receiving another investigational drug are not eligible\n* Patients who are currently receiving other anti-cancer agents are not eligible\n* Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease (GVHD) post bone marrow transplant are not eligible for this trial\n* Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed\n* Patients who have received prior therapy with a specific inhibitor of TRK (including but not limited to entrectinib [RXDX-101], DS-6051b, and PLX7486) are not eligible\n* Patients who have an uncontrolled infection are not eligible\n* Patients who have received a prior solid organ transplantation are not eligible\n* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Bone marrow infiltration except that detected by MIBG scan for neuroblastoma",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow infiltration except that detected by MIBG scan for neuroblastoma",
                    "criterion": "bone marrow infiltration",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "infiltration detected by MIBG scan for neuroblastoma"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Cytotoxic chemotherapy or other anti-cancer agents known to be myelosuppressive",
                    "criterion": "prior treatment with myelosuppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (within 7 days prior to enrollment)",
                    "criterion": "peripheral absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Elevated tumor markers in plasma or cerebrospinal fluid (CSF)",
            "criterions": [
                {
                    "exact_snippets": "Elevated tumor markers in plasma",
                    "criterion": "tumor markers in plasma",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "elevated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Elevated tumor markers in ... cerebrospinal fluid (CSF)",
                    "criterion": "tumor markers in cerebrospinal fluid (CSF)",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "elevated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0) resulting from prior therapy must be =< grade 2, with the exception of decreased tendon reflect (DTR); any grade of DTR is eligible",
            "criterions": [
                {
                    "exact_snippets": "Nervous system disorders (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0) resulting from prior therapy must be =< grade 2",
                    "criterion": "nervous system disorders resulting from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE v5.0 grade)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of decreased tendon reflect (DTR); any grade of DTR is eligible",
                    "criterion": "decreased tendon reflex (DTR)",
                    "requirements": [
                        {
                            "requirement_type": "severity (CTCAE v5.0 grade)",
                            "expected_value": "any"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have radiographically measurable disease at the time of study enrollment; patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible; measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT; Note: The following do not qualify as measurable disease:",
            "criterions": [
                {
                    "exact_snippets": "Patients must have radiographically measurable disease at the time of study enrollment",
                    "criterion": "radiographically measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of study enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "patients with neuroblastoma who do not have measurable disease but have MIBG+ evaluable disease are eligible",
                    "criterion": "MIBG+ evaluable disease in neuroblastoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurable disease",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "measurable disease in patients with CNS involvement is defined as any lesion that is at minimum 10 mm in one dimension on standard MRI or CT",
                    "criterion": "measurable disease in CNS involvement",
                    "requirements": [
                        {
                            "requirement_type": "lesion size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "imaging modality",
                            "expected_value": [
                                "MRI",
                                "CT"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment; if after the required time frame, the numerical eligibility criteria are met, e.g. blood count criteria, the patient is considered to have recovered adequately",
            "criterions": [
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior anti-cancer therapy",
                    "criterion": "recovery from acute toxic effects of prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment",
                    "criterion": "minimum duration from prior anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum_duration_since_therapy",
                            "expected_value": "meets protocol-specified minimum duration"
                        }
                    ]
                },
                {
                    "exact_snippets": "if after the required time frame, the numerical eligibility criteria are met, e.g. blood count criteria",
                    "criterion": "numerical eligibility criteria (e.g. blood count criteria)",
                    "requirements": [
                        {
                            "requirement_type": "meets_numerical_criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim) or 7 days for short-acting growth factor; for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair and the study-assigned research coordinator",
            "criterions": [
                {
                    "exact_snippets": "Hematopoietic growth factors: >= 14 days after the last dose of a long-acting growth factor (e.g. pegfilgrastim)",
                    "criterion": "time since last dose of long-acting hematopoietic growth factor",
                    "requirements": [
                        {
                            "requirement_type": "duration_since_last_dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "7 days for short-acting growth factor",
                    "criterion": "time since last dose of short-acting hematopoietic growth factor",
                    "requirements": [
                        {
                            "requirement_type": "duration_since_last_dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for growth factors that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur",
                    "criterion": "time since last dose of growth factor with prolonged adverse events",
                    "requirements": [
                        {
                            "requirement_type": "duration_since_last_dose",
                            "expected_value": "must be extended beyond the time during which adverse events are known to occur"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy (42 days if prior nitrosourea)",
            "criterions": [
                {
                    "exact_snippets": ">= 21 days after the last dose of cytotoxic or myelosuppressive chemotherapy",
                    "criterion": "time since last dose of cytotoxic or myelosuppressive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "42 days if prior nitrosourea",
                    "criterion": "time since last dose of nitrosourea",
                    "requirements": [
                        {
                            "requirement_type": "minimum time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment); (for the purpose of this study, the ULN for SGPT is 45 U/L)",
            "criterions": [
                {
                    "exact_snippets": "Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L (within 7 days prior to enrollment)",
                    "criterion": "serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT])",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 135,
                                "unit": "U/L"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with known bone marrow metastatic disease will be eligible for study provided they meet the blood counts (may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions); these patients will not be evaluable for hematologic toxicity",
            "criterions": [
                {
                    "exact_snippets": "Patients with known bone marrow metastatic disease will be eligible for study",
                    "criterion": "bone marrow metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "provided they meet the blood counts",
                    "criterion": "blood counts",
                    "requirements": [
                        {
                            "requirement_type": "meets protocol-specified values",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "may receive transfusions provided they are not known to be refractory to red cell or platelet transfusions",
                    "criterion": "refractoriness to red cell or platelet transfusions",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cellular therapy: >= 42 days after the completion of any type of cellular therapy (e.g. modified T cells, NK cells, dendritic cells, etc.)",
            "criterions": [
                {
                    "exact_snippets": "Cellular therapy: >= 42 days after the completion of any type of cellular therapy",
                    "criterion": "cellular therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
            "criterions": [
                {
                    "exact_snippets": "Leptomeningeal lesions that do not meet the measurement requirements for Response Evaluation Criteria in Solid Tumors (RECIST) 1.1",
                    "criterion": "leptomeningeal lesions",
                    "requirements": [
                        {
                            "requirement_type": "RECIST 1.1 measurement requirements",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be >= than 12 months and =< 21 years of age at the time of study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patients must be >= than 12 months and =< 21 years of age at the time of study enrollment",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age at enrollment",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "months"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 21,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",
            "criterions": [
                {
                    "exact_snippets": "Corticosteroids: if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",
                    "criterion": "corticosteroid use for immune adverse events related to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 10 to < 13 years; maximum serum creatinine (mg/dL); male: 1.2 female: 1.2",
            "criterions": [
                {
                    "exact_snippets": "Age: 10 to < 13 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 10,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 13,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 1.2 female: 1.2",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value (male)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "maximum value (female)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.2,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 13 to < 16 years; maximum serum creatinine (mg/dL); male: 1.5 female: 1.4",
            "criterions": [
                {
                    "exact_snippets": "Age: 13 to < 16 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 13,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 16,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 1.5",
                    "criterion": "serum creatinine (male)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); ... female: 1.4",
                    "criterion": "serum creatinine (female)",
                    "requirements": [
                        {
                            "requirement_type": "maximum value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.4,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients and/or their parents or legally authorized representatives must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines",
            "criterions": [
                {
                    "exact_snippets": "All patients and/or their parents or legally authorized representatives must sign a written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "assent, when appropriate, will be obtained according to institutional guidelines",
                    "criterion": "assent",
                    "requirements": [
                        {
                            "requirement_type": "obtained when appropriate",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin >= 2 g/dL (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin >= 2 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans) except as noted for neuroblastoma",
            "criterions": [
                {
                    "exact_snippets": "Lesions only detected by nuclear medicine studies (e.g., bone, gallium or positron emission tomography [PET] scans)",
                    "criterion": "lesions detected by nuclear medicine studies",
                    "requirements": [
                        {
                            "requirement_type": "detection_method",
                            "expected_value": [
                                "bone scan",
                                "gallium scan",
                                "positron emission tomography (PET) scan"
                            ]
                        },
                        {
                            "requirement_type": "detection_exclusivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: >= 16 years; maximum serum creatinine (mg/dL); male: 1.7 female: 1.4",
            "criterions": [
                {
                    "exact_snippets": "Age: >= 16 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 1.7 female: 1.4",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value (male)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.7,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "maximum value (female)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.4,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Months",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Months",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil [ANC] counts): >= 7 days after the last dose of agent; for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment",
            "criterions": [
                {
                    "exact_snippets": "Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil [ANC] counts): >= 7 days after the last dose of agent",
                    "criterion": "prior anti-cancer agent exposure (non-myelosuppressive)",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned research coordinator prior to enrollment",
                    "criterion": "prior anti-cancer agent exposure (unlisted agents)",
                    "requirements": [
                        {
                            "requirement_type": "discussion with study chair and research coordinator",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Previously radiated lesions that have not demonstrated clear progression post radiation",
            "criterions": [
                {
                    "exact_snippets": "Previously radiated lesions",
                    "criterion": "lesions",
                    "requirements": [
                        {
                            "requirement_type": "prior radiation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "have not demonstrated clear progression post radiation",
                    "criterion": "lesions",
                    "requirements": [
                        {
                            "requirement_type": "progression after radiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Stem cell Infusions (with or without total body irradiation [TBI]):",
            "criterions": [
                {
                    "exact_snippets": "Stem cell Infusions (with or without total body irradiation [TBI])",
                    "criterion": "stem cell infusions",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "with or without total body irradiation [TBI]",
                    "criterion": "total body irradiation (TBI)",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": "with or without"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy",
            "criterions": [
                {
                    "exact_snippets": "Radiopharmaceutical therapy (e.g., radiolabeled antibody, 131I-MIBG): >= 42 days after systemically administered radiopharmaceutical therapy",
                    "criterion": "systemically administered radiopharmaceutical therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 2 to < 6 years; maximum serum creatinine (mg/dL); male: 0.8 female: 0.8",
            "criterions": [
                {
                    "exact_snippets": "Age: 2 to < 6 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 6,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 0.8 female: 0.8",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value (male)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.8,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "maximum value (female)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.8,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must not have received prior exposure to other NTRK inhibitors including but not limited to LOXO-101 (larotrectinib), entrectinib (RXDX-101), DS6051, PLX7486",
            "criterions": [
                {
                    "exact_snippets": "must not have received prior exposure to other NTRK inhibitors including but not limited to LOXO-101 (larotrectinib), entrectinib (RXDX-101), DS6051, PLX7486",
                    "criterion": "prior exposure to NTRK inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignant fluid collections (e.g., ascites, pleural effusions)",
            "criterions": [
                {
                    "exact_snippets": "Malignant fluid collections (e.g., ascites, pleural effusions)",
                    "criterion": "malignant fluid collections",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pleural effusions",
                    "criterion": "pleural effusions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For patients with solid tumors without known bone marrow involvement:",
            "criterions": [
                {
                    "exact_snippets": "solid tumors",
                    "criterion": "solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "without known bone marrow involvement",
                    "criterion": "bone marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "known involvement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Autologous stem cell infusion including boost infusion: >= 42 days",
            "criterions": [
                {
                    "exact_snippets": "Autologous stem cell infusion including boost infusion: >= 42 days",
                    "criterion": "autologous stem cell infusion (including boost infusion)",
                    "requirements": [
                        {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2 (within 7 days prior to enrollment) or",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance ... >= 70 ml/min/1.73 m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "ml/min/1.73 m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radioisotope glomerular filtration rate (GFR) >= 70 ml/min/1.73 m^2",
                    "criterion": "radioisotope glomerular filtration rate (GFR)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 70,
                                "unit": "ml/min/1.73 m^2"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A serum creatinine based on age/gender as follows (within 7 days prior to enrollment):",
            "criterions": [
                {
                    "exact_snippets": "A serum creatinine based on age/gender as follows (within 7 days prior to enrollment)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "value based on age/gender",
                            "expected_value": "as follows (within 7 days prior to enrollment)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Bilirubin (sum of conjugated + unconjugated) =< 1.5 x upper limit of normal (ULN) for age (within 7 days prior to enrollment)",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN for age"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count >= 100,000/mm^3 (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment) (within 7 days prior to enrollment)",
            "criterions": [
                {
                    "exact_snippets": "Platelet count >= 100,000/mm^3 ... (within 7 days prior to enrollment)",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "mm^3"
                            }
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 7 days prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": "at least 7 days prior to enrollment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT; >= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis; >= 42 days if other substantial brain metastases (BM) radiation; Note: radiation may not be delivered to \"measurable disease\" tumor site(s) being used to follow response to subprotocol treatment",
            "criterions": [
                {
                    "exact_snippets": "Radiation therapy (XRT)/external beam irradiation including protons: >= 14 days after local XRT",
                    "criterion": "time since local external beam radiation therapy (XRT)",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">= 150 days after TBI, craniospinal XRT or if radiation to >= 50% of the pelvis",
                    "criterion": "time since total body irradiation (TBI), craniospinal XRT, or radiation to >= 50% of the pelvis",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 150,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": ">= 42 days if other substantial brain metastases (BM) radiation",
                    "criterion": "time since substantial brain metastases (BM) radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 42,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation may not be delivered to \"measurable disease\" tumor site(s) being used to follow response to subprotocol treatment",
                    "criterion": "radiation to measurable disease tumor sites used for response assessment",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "no radiation delivered"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1",
            "criterions": [
                {
                    "exact_snippets": "Antibodies: >= 21 days must have elapsed from infusion of last dose of antibody",
                    "criterion": "time since last antibody infusion",
                    "requirements": [
                        {
                            "requirement_type": "elapsed time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "toxicity related to prior antibody therapy must be recovered to grade =< 1",
                    "criterion": "toxicity from prior antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "toxicity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": ""
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 1 to < 2 years; maximum serum creatinine (mg/dL); male: 0.6 female: 0.6",
            "criterions": [
                {
                    "exact_snippets": "Age: 1 to < 2 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 2,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 0.6 female: 0.6",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value (male)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.6,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "maximum value (female)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 0.6,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with seizure disorder may be enrolled if on anti-convulsants and well controlled",
            "criterions": [
                {
                    "exact_snippets": "Patients with seizure disorder may be enrolled",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if on anti-convulsants",
                    "criterion": "anti-convulsant use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "well controlled",
                    "criterion": "seizure disorder control",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 21 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 21 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)",
            "criterions": [
                {
                    "exact_snippets": "Interleukins, interferons and cytokines (other than hematopoietic growth factors): >= 21 days after the completion of interleukins, interferon or cytokines (other than hematopoietic growth factors)",
                    "criterion": "prior interleukins, interferons, or cytokines (other than hematopoietic growth factors) therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 21,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age: 6 to < 10 years; maximum serum creatinine (mg/dL); male: 1 female: 1",
            "criterions": [
                {
                    "exact_snippets": "Age: 6 to < 10 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 10,
                                        "unit": "years"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "maximum serum creatinine (mg/dL); male: 1 female: 1",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "maximum value (male)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "mg/dL"
                            }
                        },
                        {
                            "requirement_type": "maximum value (female)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Karnofsky >= 50% for patients > 16 years of age and Lansky >= 50 for patients =< 16 years of age; Note: neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky >= 50% for patients > 16 years of age",
                    "criterion": "Karnofsky performance status",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky >= 50 for patients =< 16 years of age",
                    "criterion": "Lansky performance status",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "neurologic deficits in patients with CNS tumors must have been relatively stable for at least 7 days prior to study enrollment",
                    "criterion": "neurologic deficits stability in CNS tumor patients",
                    "requirements": [
                        {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score",
                    "criterion": "ambulatory status for performance score assessment",
                    "requirements": [
                        {
                            "requirement_type": "ambulatory_status_override",
                            "expected_value": "patients unable to walk due to paralysis but up in a wheelchair are considered ambulatory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* APEC1621SC: Patient must have enrolled onto APEC1621SC and must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621A based on the presence of an actionable mutation as defined in APEC1621SC",
            "criterions": [
                {
                    "exact_snippets": "Patient must have enrolled onto APEC1621SC",
                    "criterion": "enrollment in APEC1621SC",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have been given a treatment assignment to Molecular Analysis for Therapy Choice (MATCH) to APEC1621A",
                    "criterion": "treatment assignment to APEC1621A (MATCH)",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "based on the presence of an actionable mutation as defined in APEC1621SC",
                    "criterion": "actionable mutation (as defined in APEC1621SC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocyte infusion (DLI) or boost infusion: >= 84 days after infusion and no evidence of graft versus host disease (GVHD)",
            "criterions": [
                {
                    "exact_snippets": "Allogeneic (non-autologous) bone marrow or stem cell transplant, or any stem cell infusion including donor leukocyte infusion (DLI) or boost infusion: >= 84 days after infusion",
                    "criterion": "allogeneic bone marrow or stem cell transplant or any stem cell infusion (including DLI or boost infusion)",
                    "requirements": [
                        {
                            "requirement_type": "time since infusion",
                            "expected_value": {
                                "operator": ">=",
                                "value": 84,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of graft versus host disease (GVHD)",
                    "criterion": "graft versus host disease (GVHD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patients who are currently receiving another investigational drug are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who are currently receiving another investigational drug are not eligible",
                    "criterion": "current receipt of another investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are currently receiving other anti-cancer agents are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who are currently receiving other anti-cancer agents are not eligible",
                    "criterion": "current use of other anti-cancer agents",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible; strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study; Note: CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed",
            "criterions": [
                {
                    "exact_snippets": "Patients who are currently receiving drugs that are strong inducers or inhibitors of CYP3A4 are not eligible",
                    "criterion": "current use of strong CYP3A4 inducers or inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "strong inducers or inhibitors of CYP3A4 should be avoided from 14 days prior to enrollment to the end of the study",
                    "criterion": "use of strong CYP3A4 inducers or inhibitors during screening and study",
                    "requirements": [
                        {
                            "requirement_type": "avoidance_period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days before enrollment"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed",
                    "criterion": "use of CYP3A4 inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases",
                    "requirements": [
                        {
                            "requirement_type": "allowed_if_stable_dose",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received a prior solid organ transplantation are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received a prior solid organ transplantation are not eligible",
                    "criterion": "prior solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible; if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",
            "criterions": [
                {
                    "exact_snippets": "Patients receiving corticosteroids who have not been on a stable or decreasing dose of corticosteroid for at least 7 days prior to enrollment are not eligible",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable or decreasing"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "timing relative to enrollment",
                            "expected_value": "prior to enrollment"
                        }
                    ]
                },
                {
                    "exact_snippets": "if used to modify immune adverse events related to prior therapy, >= 14 days must have elapsed since last dose of corticosteroid",
                    "criterion": "corticosteroid use for immune adverse events related to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease (GVHD) post bone marrow transplant are not eligible for this trial",
            "criterions": [
                {
                    "exact_snippets": "Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease (GVHD) post bone marrow transplant are not eligible",
                    "criterion": "use of agents to prevent graft-versus-host disease (GVHD) post bone marrow transplant",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with the safety monitoring requirements of the study",
                    "criterion": "ability to comply with safety monitoring requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have received prior therapy with a specific inhibitor of TRK (including but not limited to entrectinib [RXDX-101], DS-6051b, and PLX7486) are not eligible",
            "criterions": [
                {
                    "exact_snippets": "Patients who have received prior therapy with a specific inhibitor of TRK (including but not limited to entrectinib [RXDX-101], DS-6051b, and PLX7486) are not eligible",
                    "criterion": "prior therapy with a specific inhibitor of TRK",
                    "requirements": [
                        {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... will not be entered on this study",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding women will not be entered on this study",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "breast-feeding",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnancy tests must be obtained in girls who are post-menarchal",
                    "criterion": "pregnancy test in post-menarchal girls",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test",
                            "expected_value": "must be obtained"
                        }
                    ]
                },
                {
                    "exact_snippets": "males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method for the duration of study treatment",
                    "criterion": "contraceptive use in participants of reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use",
                            "expected_value": "agreed to use effective method for duration of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have an uncontrolled infection are not eligible",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}